The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Abstract
OBJECTIVES: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside clinical trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring in patients receiving tigecycline for other indications. The possible mechanisms of resistance and pharmacokinetic limitations of the drug are addressed. METHODS: The clinical records of involved patients were systematically reviewed. Tigecycline susceptibility testing was initially performed using the Etest method and confirmed by agar dilution. Involved isolates underwent PFGE and exposure to phenyl-arginine-beta-naphthylamide (PAbetaN), an efflux pump inhibitor. RESULTS: Two patients developed A. baumannii bloodstream infection while receiving tigecycline. Tigecycline was administered for other indications for 9 and 16 days, respectively, before the onset of A. baumannii infection. Patient 1 died of overwhelming A. baumannii infection and Patient 2 recovered after a change in antibiotic therapy. The MICs of tigecycline were 4 and 16 mg/L, respectively. Both isolates had a multidrug-resistant phenotype and were genotypically unrelated. After exposure to PAbetaN, the MICs reduced to 1 and 4 mg/L, respectively. CONCLUSIONS: To our knowledge, this is the first clinical description of bloodstream infection caused by tigecycline-non-susceptible A. baumannii. Such resistance appears to be at least partly attributable to an efflux pump mechanism. Given the reported low serum tigecycline levels, we urge caution when using this drug for treatment of A. baumannii bloodstream infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286 · cited 1×
“, with intrinsic resistance being mediated by chromosomally encoded multidrug efflux pumps from the resistance-nodulation-division (RND) family.(3,4) Thus far, resistance to tigecycline in a clinical setting has rarely been described, with unpublished reports suggesting several instances of emerging resistance during…”
BackgroundVisalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165 · cited 2×
“, with intrinsic resistance being mediated by chromosomally encoded multidrug efflux pumps from the resistance-nodulation-division (RND) family.(3,4) Thus far, resistance to tigecycline in a clinical setting has rarely been described, with unpublished reports suggesting several instances of emerging resistance during…”
Background
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Self-citationAn increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii
Dijkshoorn, L., Nemec, A., & Seifert, H. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1789 · Cited by 1,828
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Hospital-Acquired Infections Due to Gram-Negative Bacteria
Peleg, A. Y., & Hooper, D. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0904124 · Cited by 1,495
Self-citationGlobal Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Beceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,070
Maragakis, L. L., & Perl, T. M. (2008) · Clinical Infectious Diseases · doi:10.1086/529198 · Cited by 969
Efflux-Mediated Drug Resistance in Bacteria: An Update
Li, X.-Z., & Nikaido, H. (2009) · Drugs · doi:10.2165/11317030-000000000-00000 · Cited by 966
Munoz-Price, L. S., & Weinstein, R. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra070741 · Cited by 772
Tetracycline Antibiotics and Resistance
Grossman, T. H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025387 · Cited by 725
Metallo-β-lactamases: a last frontier for β-lactams?
Cornaglia, G., Giamarellou, H., & Rossolini, G. M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70056-1 · Cited by 613
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli
Giske, C. G., Monnet, D. L., Cars, O., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01169-07 · Cited by 610
Efflux pumps as antimicrobial resistance mechanisms
Poole, K. (2007) · Annals of Medicine · doi:10.1080/07853890701195262 · Cited by 562
Efflux-Mediated Antibiotic Resistance in Acinetobacter spp
Coyne, S., Courvalin, P., & Périchon, B. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01388-10 · Cited by 505
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
The Ecology, Biology and Pathogenesis of Acinetobacter spp.: An Overview
Doughari, H. J., Ndakidemi, P. A., Human, I. S., & Benade, S. (2011) · Microbes and Environments · doi:10.1264/jsme2.me10179 · Cited by 453
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe
Souli, M., Galani, I., & Giamarellou, H. (2008) · Eurosurveillance · doi:10.2807/ese.13.47.19045-en · Cited by 436
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 435
Kempf, M., & Rolain, J.-M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.10.004 · Cited by 389
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Gordon, N. C., & Wareham, D. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.024 · Cited by 378
The growing burden of antimicrobial resistance
Hawkey, P. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn241 · Cited by 377
Treatment of Acinetobacter Infections
Fishbain, J., & Peleg, A. Y. (2010) · Clinical Infectious Diseases · doi:10.1086/653120 · Cited by 358
Self-citationDamier-Piolle, L., Magnet, S., Brémont, S., Lambert, T., & Courvalin, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00732-07 · Cited by 357
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04121-1 · Cited by 332
Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Murray, G., Peleg, A., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398388 · Cited by 316
Self-citationZavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
Acinetobacter baumannii: a universal threat to public health?
Giamarellou, H., Antoniadou, A., & Kanellakopoulou, K. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.02.013 · Cited by 258
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Self-citationEscalating antimicrobial resistance among Enterobacteriaceae: Focus on carbapenemases
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904891 · Cited by 58
Metadata
- Authors
- Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-28
- Volume
- 59
- Issue
- 1
- Pages
- 128-131
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2159068753
- Cited by
- 248
- References
- 2
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.